UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more
An officer at UroGen Pharma Ltd. (NASDAQ: URGN), Mark Schoenberg, plans to sell additional common shares through RBC Capital Markets LLC. This follows previous sales in June and July 2026, totaling 20,000 shares for $750,151, which were acquired via a stock option exercise in January 2023. The filing indicates a neutral impact and sentiment regarding these planned sales.
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
This M&A roundup highlights two key biopharma agreements. UroGen Pharma has invested up to $7 million in IntraGel Therapeutics, securing an exclusive option to license Tumocure for advanced head and neck cancer and access to IntraGel's SRGel platform. Separately, Lupin Limited's subsidiary, VISUfarma B.V., has entered into an exclusive licensing agreement with Tenpoint Therapeutics to commercialize Yuvezzi, an ophthalmic product for presbyopia, across Europe.
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd.
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd. The funding involves UroGen Pharma participating in an investment agreement to purchase convertible preferred stock from IntraGel. This development follows UroGen Pharma's recent submission of a New Drug Application to the FDA for UGN-103 in recurrent bladder cancer and several analyst rating adjustments.
UroGen Pharma secures option to license IntraGel SRGel program, agrees up to $7M investment
UroGen Pharma has entered into an agreement with IntraGel, securing an exclusive option to license IntraGel’s SRGel-based TumoCure program for head and neck cancer. This agreement also includes options for additional worldwide licenses to combine SRGel with other compounds, expanding UroGen's potential pipeline. Additionally, UroGen will invest up to $7 million in IntraGel equity to support this collaboration.
UroGen Pharma secures option deal with IntraGel for cancer tech
UroGen Pharma has entered into a strategic option and research license agreement with IntraGel Therapeutics, including an equity investment of up to $7 million. This deal grants UroGen exclusive options to develop up to three oncology products utilizing IntraGel's SRGel platform, a biodegradable sustained-release drug delivery technology. The agreement also includes an exclusive option for TumoCure, an investigational therapy for advanced head and neck cancer, following its Phase 2 clinical study completion.
UroGen Announces Strategic Collaboration and Investment
UroGen Pharma Ltd. has entered into a strategic Option and Research License Agreement and an Investment Agreement with IntraGel Therapeutics, Ltd. This collaboration grants UroGen access to IntraGel's proprietary SRGel platform for developing oncology products and an exclusive option to license TumoCure, an investigational therapy for advanced head and neck cancer. UroGen will also invest up to $7 million in IntraGel.
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
IntraGel Therapeutics and UroGen Pharma have announced strategic collaboration and investment agreements focused on advancing sustained-release investigational oncology therapies. UroGen will invest up to $7 million in IntraGel, supporting the Phase 2 clinical development of TumoCure for head and neck cancer. Additionally, UroGen gains access to IntraGel's proprietary SRGel™ platform for localized drug delivery and an exclusive option to acquire worldwide rights to TumoCure and potentially develop up to three more oncology products using the SRGel platform.
UroGen Announces Strategic Collaboration and Investment
UroGen Pharma Ltd. announced a strategic Option and Research License Agreement and an Investment Agreement with IntraGel Therapeutics, Ltd. This collaboration grants UroGen access to IntraGel's proprietary SRGel platform for developing up to three oncology products and an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer. UroGen will also invest up to $7 million in IntraGel.
Urogen Pharma stock hits 52-week high at 49.69 USD
Urogen Pharma (URGN) stock has reached a new 52-week high of $49.69, currently trading slightly below this peak at $49.81. This surge reflects an impressive 158.56% increase over the past year and 109% year-to-date returns, driven by strong revenue growth and significant gross profit margins. The company's recent Q2 2026 revenue of $72.5 million, boosted by its bladder-cancer drug ZUSDURI, surpassed analyst forecasts, leading Guggenheim to raise its price target to $58.
Rice Hall James & Associates LLC Purchases Shares of 300,650 Urogen Pharma $URGN
Rice Hall James & Associates LLC has acquired a new stake of 300,650 shares in Urogen Pharma (NASDAQ:URGN), valued at approximately $11.1 million, representing about 0.62% of the company. Despite Urogen Pharma reporting quarterly revenue above expectations, it missed earnings per share estimates, and insiders sold over 25,000 shares recently. The stock currently holds a "Moderate Buy" consensus from analysts with an average target price of $50.38.
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
UroGen Pharma Ltd. has submitted a New Drug Application (NDA) to the U.S. FDA for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The submission is supported by Phase 3 UTOPIA trial data, which showed a 77.8% three-month complete response rate and a 94.5% six-month duration of response. UGN-103 leverages UroGen's RTGel technology, aiming for improved manufacturing, reconstitution, and extended shelf-life compared to its predecessor, ZUSDURI.
Ninety-nine patients entered a bladder cancer trial—what came next?
UroGen Pharma has submitted a New Drug Application (NDA) to the FDA for UGN-103, an investigational treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The submission is supported by data from the Phase 3 UTOPIA trial, which showed a 77.8% three-month complete response rate and a 94.5% six-month duration of response. UGN-103 leverages UroGen's RTGel sustained-release technology, building upon the foundation of their FDA-approved drug ZUSDURI, with intellectual property coverage expected until July 2044.
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence?
UroGen Pharma (URGN) is experiencing increased investor confidence following strong Q2 2026 earnings, which showed higher sales and a smaller net loss, alongside positive updates on ZUSDURI adoption and JELMYTO patent litigation. Despite a significant share price surge, there's a debate regarding its valuation; one narrative suggests it's 33.3% overvalued at $48.12 compared to a $36.11 fair value, while Simply Wall St's DCF model indicates a much higher fair value of $358.39. The company's shift towards minimally invasive therapies and long-term durability data for ZUSDURI contribute to its improved market perception, though risks like ongoing losses and concentrated revenue exposure remain.
California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN
The California State Teachers Retirement System significantly increased its holdings in Urogen Pharma (NASDAQ:URGN) by 1,605.5% in the first quarter, now owning 38,750 shares valued at $697,000. Institutional investors collectively hold 91.29% of the company, which has an average analyst rating of "Moderate Buy" and a consensus price target of $48.78. Despite reporting higher-than-expected revenue of $72.46 million, Urogen Pharma posted a loss of $0.28 per share, slightly missing analyst estimates.
Is UroGen Pharma (URGN) Overvalued As Sales Growth And Patent Clarity Lift Confidence?
UroGen Pharma (URGN) is experiencing increased attention following strong Q2 2026 earnings, which showed higher sales and progress on product adoption and patent litigation. Despite a significant share price increase of over 100% year-to-date, there's a valuation debate, with a popular narrative suggesting the stock is 33.3% overvalued at $48.12 compared to a $36.11 fair value, while Simply Wall St's DCF model indicates a much higher future cash flow value of $358.39. The article advises investors to review both upside potential and risks, including ongoing losses and concentrated revenue.
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Urogen Pharma (URGN) is highlighted as a strong momentum pick due to its "A" Momentum Style Score from Zacks and a Zacks Rank of #2 (Buy). The article details URGN's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. Additionally, positive earnings estimate revisions further support its potential for near-term growth.
(URGN) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily discusses Urogen Pharma Ltd. (NASDAQ: URGN) and presents AI-generated trading strategies based on volatility zones. It highlights strong sentiment across all time horizons supporting an overweight bias, notes the absence of resistance levels above the current price, and provides specific entry, target, and stop-loss levels for long, breakout, and short strategies.
UroGen Pharma (URGN): TD Bank group discloses 3.37M shares, 6.9% beneficial stake
The Toronto-Dominion Bank and TD Securities Inc. have jointly reported beneficial ownership of 3,371,263 ordinary shares of UroGen Pharma Ltd. This represents a 6.9% stake in the company. The filing specifies the individual voting and dispositive powers of both TD Bank and TD Securities over these shares, clarifying that TD Bank disclaims beneficial ownership of TD Securities' shares except for its pecuniary interest.
UroGen (URGN) Q2 2026 Earnings Call Transcript
UroGen Pharma (URGN) reported strong Q2 2026 results driven by the ZUSDURI launch, with total revenue reaching $72.5 million. ZUSDURI's commercial demand is expanding into community urology practices, showing increased repeat utilization and physician confidence. The company is advancing its pipeline with NDA submissions for UGN-103 and progression of UGN-501, and remains on track for profitability using existing capital despite increased marketing and development investments.
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Time to Buy?
Urogen Pharma (NASDAQ:URGN) recently reached a new 52-week high of $48.21, reflecting generally positive analyst sentiment with a "Moderate Buy" consensus rating and price targets up to $75. Despite exceeding revenue expectations with $72.46 million, the company missed EPS estimates, reporting a loss of $0.28 per share. Insider selling and substantial institutional ownership (91.29%) characterize recent trading activity.
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?
UroGen Pharma (URGN) reported strong Q2 2026 results with sales tripling to US$72.46 million and net loss narrowing to US$14.35 million. This performance, along with expanded loan facilities, supports the company's investment narrative of scaling its urology-focused drugs, though it remains unprofitable. Analysts project significant revenue growth by 2029, but investors are cautioned about continued operating losses and negative equity.
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against UroGen Pharma Ltd. (NASDAQ:URGN) on behalf of investors who purchased securities between July 27, 2023, and May 15, 2025. The lawsuit alleges that UroGen made misleading statements and failed to disclose critical information regarding the design and prospects of its ENVISION clinical study for UGN-102, which posed a substantial risk to FDA approval. Investors with losses have until July 28, 2025, to seek appointment as lead plaintiff.
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?
UroGen Pharma (URGN) reported significantly improved Q2 2026 results, with revenue tripling to US$72.46 million and net loss narrowing to US$14.35 million. These results indicate emerging operating leverage, supported by an expanded loan facility, which provides financial flexibility despite the company remaining unprofitable. While the strong performance supports the investment narrative, UroGen Pharma's reliance on capital access and sustained commercial execution due to continued operating losses and negative equity remains a key risk.
UroGen Pharma (URGN) Is Up 21.7% After Q2 Revenue Triples And Loss Narrows Has The Bull Case Changed?
UroGen Pharma (URGN) saw its stock rise by 21.7% after reporting significant improvements in its Q2 2026 results, with revenue tripling to US$72.46 million and net loss narrowing. The company's first-half sales nearly tripled, and its net loss was halved, suggesting emerging operating leverage. While these results and an expanded loan facility provide financial flexibility and support the company's growth narrative, UroGen Pharma remains unprofitable with negative equity, highlighting its dependence on continued commercial execution and capital access.
UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run
UroGen Pharma (URGN) has seen a significant 210% return over the last five years, but its current valuation suggests the stock is now fairly priced rather than undervalued. The company's P/S ratio is aligned with its modelled fair P/S, indicating no clear discount or premium. While future revenue growth and pipeline conversion could support the valuation, ongoing funding needs and execution risks limit further upside.
Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright
HC Wainwright has raised its Q3 2026 EPS estimate for Urogen Pharma to a loss of $0.07 per share from a previous loss of $0.37, while maintaining a "Buy" rating and a $75 price target. This positive adjustment comes as Urogen Pharma’s Q2 revenue of $72.46 million exceeded analyst forecasts, despite a slight miss on EPS. The company currently holds a "Moderate Buy" consensus rating with an average price target of $48.78.
UroGen Pharma Ltd. Revenue Breakdown – MUN:UR8
UroGen Pharma Ltd. (MUN:UR8) generated €93.49 million in revenue last year, primarily from its RTGel Reverse Thermal Hydrogel segment, which accounted for €93.48 million. The majority of this revenue, €93.48 million, originated from Israel and the United States. This represents an increase from the previous year's segment revenue of €87.32 million.
Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed
UroGen Pharma (URGN) saw its stock rise 22.8% after reporting a nearly tripling of Q2 2026 revenue to US$72.46 million and a significant narrowing of its net loss to US$14.35 million. While the company's improved operating leverage supports its growth thesis, concerns remain regarding its cash runway and dependence on external funding, despite an expanded loan facility. Analysts project substantial revenue growth and a move to profitability by 2029, though fair value estimates suggest a potential downside from its current price.
UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus
UroGen Pharma (URGN) reported strong Q2 2026 results, with increased sales and a reduced net loss, leading to significant stock price appreciation. This has sparked debate over its fair value, with one narrative suggesting it's 30% overvalued at $36.11, while another Discounted Cash Flow model indicates it is significantly undervalued at $355.54 per share. Investors are now evaluating whether the recent gains fully reflect its potential or if further upside exists.
UroGen Pharma (URGN) Stock Looks Fairly Priced Despite Its 210% Run
UroGen Pharma's stock has seen a significant 210% return over the last five years, but its current valuation suggests it is now fairly priced rather than a bargain. While its potential revenue growth and pipeline support the current valuation, ongoing funding needs and execution risks might limit further price increases. The company trades at about 12.2x sales, slightly above the industry average, and its P/S ratio indicates it's roughly fairly valued.
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts
Analysts have significantly upgraded their forecasts for UroGen Pharma Ltd. (NASDAQ:URGN), increasing revenue estimates to $322 million for 2026 and sharply reducing the anticipated loss per share to US$0.14. This positive revision, reflecting strong business fundamentals and accelerated growth expectations, has led to a 30% increase in the consensus price target to US$58.25. The company is also projected to achieve profitability within the next few years.
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts
Analysts have significantly upgraded their forecasts for UroGen Pharma Ltd. (NASDAQ:URGN), increasing revenue estimates to $322 million for 2026 and sharply reducing the anticipated loss per share to $0.14. This positive revision reflects a projected 191% annualized revenue growth, much faster than the industry average, and has led to a 30% increase in the consensus price target to US$58.25. The company is now expected to approach profitability sooner, making it a potentially attractive investment.
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts
Analysts have significantly upgraded their forecasts for UroGen Pharma Ltd. (NASDAQ:URGN), increasing revenue estimates and reducing projected losses for 2026. The consensus price target has also risen by 30%, indicating a universally bullish sentiment. This positive outlook suggests UroGen Pharma is expected to grow much faster than its industry and is anticipated to reach break-even within the next few years.
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60
Oppenheimer has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and increased its price target to $60. This reflects continued confidence in the company's prospects and potential for growth.
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75
This article provides an overview of recent analyst ratings for UroGen Pharma Ltd (URGN.US), highlighting a consensus among six analysts with a price target range of $48 to $75. The analysis suggests a potential upside of over 100% based on the current share price, with an average target price of $61.67. The article also includes a summary of analyst actions, ratings, and price targets.
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60
TD Cowen has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and increased its price target to $60. This reflects a positive outlook from the firm regarding the company's financial prospects and market performance.
UroGen Pharma Ltd. (URGN) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of UroGen Pharma Ltd. (URGN) stock, including its real-time price, market performance, and company profile. It details key financial metrics, earnings trends, analyst ratings, and product pipeline, highlighting its focus on urothelial and specialty cancers.
Urogen Pharma Q2 2026 Earnings Call Transcript
Urogen Pharma reported strong Q2 2026 results, with ZUSDURI revenue reaching $50.4 million, a 73% sequential increase, driven by expanding adoption in both hospital and community practices. The company also announced durable clinical results for ZUSDURI and plans for further pipeline advancements, including NDA submission for UGN-103 and initiation of a Phase I study for UGN-501. Despite increased operating expenses for promotional activities and pipeline development, Urogen Pharma remains confident in reaching profitability with existing capital resources.
UroGen Pharma 2Q Loss $14.4M >URGN
UroGen Pharma reported a second-quarter net loss of $14.4 million. This financial update, released by the company, indicates its performance for the specified period.
Urogen Pharma Q2 Earnings Call Highlights
Urogen Pharma (NASDAQ: URGN) reported a significant increase in Q2 2026 revenue to $72.5 million, primarily driven by strong ZUSDURI net product sales of $50.4 million. The company also narrowed its net loss to $14.4 million and saw expanded adoption of ZUSDURI, particularly in community practices. UroGen advanced its pipeline, with UGN-103's NDA filing on track, and raised its 2026 operating expense guidance to $260 million-$270 million to support continued commercial and development investments.
Urogen Pharma stock hits 52-week high at 43.97 USD
Urogen Pharma's stock has reached a new 52-week high of $43.97, reflecting a significant 116.89% increase over the past year. This surge is supported by positive analyst ratings, an increased price target from Oppenheimer for its Jelmyto product, and regulatory clearance for its UGN-501 bladder cancer candidate. Despite an InvestingPro analysis suggesting the stock is overvalued, these developments signal strong investor confidence and potential future growth.
URGN Stock Jumps As Street Hikes Targets On Patent Wins
UroGen Pharma (URGN) stock surged over 15% following multiple analyst target hikes and news of significant patent wins. Oppenheimer, Goldman Sachs, and Guggenheim raised their price targets, citing strong sales forecasts for Zusduri, early launch traction, and a new patent extending protection until 2044. The company also received FDA clearance for a new bladder cancer trial, further boosting investor confidence.
Earnings call transcript: UroGen Pharma tops Q2 2026 revenue forecast
UroGen Pharma reported strong Q2 2026 revenue of $72.5 million, significantly exceeding forecasts, driven by the successful launch of its bladder-cancer drug ZUSDURI. The company's net loss narrowed to $14.4 million, and shares climbed 11.9% in premarket trading. Management increased full-year operating expense guidance to support ZUSDURI's launch and pipeline development, while maintaining confidence in reaching profitability with existing capital.
UroGen Pharma Q2 Net Loss Narrows, Revenue Rises
UroGen Pharma reported a narrowed net loss of $28.3 million for Q2, down from $37.4 million in the prior year, while revenue increased to $16.7 million from $12.3 million. The company's lead product, Jelmyto, saw increased sales. UroGen Pharma also announced a recent private placement generating $120 million in gross proceeds.
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) reported a Q2 loss of $0.28 per share, outperforming the Zacks Consensus Estimate of a $0.38 loss, and revenues of $72.46 million, exceeding estimates by 16.42%. The company's shares have risen 70.5% year-to-date, and it currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance. Investors are now looking to management's commentary on the earnings call and future earnings estimates for continued guidance.
Urogen Pharma Ltd reports results for the quarter ended June 30 - Earnings Summary
Urogen Pharma Ltd has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief overview of the company's financial performance during this period. Readers can access the full report via TradingView.
UroGen Q2 revenue jumps to $72.5 million on ZUSDURI launch
UroGen Pharma (URGN) reported a significant increase in Q2 2026 revenue, reaching $72.5 million, largely due to the successful commercial launch of ZUSDURI, which contributed $50.4 million. Despite a net loss of $14.4 million, the company's financial position remains stable with $108.0 million in cash and equivalents. UroGen also updated its full-year guidance for JELMYTO net product revenue and operating expenses, while providing positive updates on its UGN-103 and UGN-501 clinical programs.
Q3 2025 Urogen Pharma Ltd Earnings Call Transcript
UroGen Pharma Ltd (URGN) reported strong preliminary demand revenue for October 2025, significantly increasing over the prior three months, and has secured broad insurance coverage for its products. The company is expanding its sales force and is on track for an NDA submission for EGN 103 in late 2026, with anticipated approval in 2027. Despite these positive developments, the company faces challenges with slower-than-expected Zyturi uptake due to logistical and reimbursement issues, increased R&D expenses, and a higher net loss in Q3 2025 compared to the previous year.
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
UroGen Pharma Ltd. announced strong financial results for Q2 2026, with ZUSDURI generating $50.4 million in revenue, a 73% quarter-over-quarter increase, and reported a significant new U.S. patent allowance extending protection for ZUSDURI and UGN-103 into July 2044. The company is advancing its pipeline, with UGN-103 on track for NDA submission in Q3 2026 and UGN-501 expected to begin a Phase 1 trial in Q4 2026, reinforcing its confidence in building a durable commercial franchise. Despite a slight decrease in JELMYTO revenue compared to the previous year, UroGen maintains its full-year guidance for JELMYTO and is increasing operating expenses to accelerate investment in ZUSDURI and pipeline development.
Price-Driven Insight from (URGN) for Rule-Based Strategy
This article from Stock Traders Daily provides a price-driven insight for Urogen Pharma Ltd. (NASDAQ: URGN), highlighting weak near-term sentiment but strong mid- to long-term outlook. It details specific institutional trading strategies (Long, Breakout, Short) with entry, target, and stop-loss levels, alongside a multi-timeframe signal analysis for support and resistance.
